BioNTech, CureVac part of $3.14B deal to bolster German vaccine capacity through 2029: report

Homegrown mRNA players BioNTech and CureVac have signed on to supply Germany with vaccines against future health emergencies for years to come.

Germany will pay upward of 2.86 billion euros ($3.14 billion) to lock up local vaccine production capacity through 2029, Reuters reports, citing the country’s economy ministry. Wednesday, the German government approved plans to sign contracts with mRNA specialist BioNTech plus the partnership between CureVac and GlaxoSmithKline. Also involved are contract manufacturers Wacker, CordenPharma, Celonic and IDT, the news outlet said.